NCT07650708招募中4 期
A Multicenter, Open-Label Study to Evaluate Perioperative Treatment of Dry Eye With Miebo® in Subjects Undergoing LASIK
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 100
- 试验地点
- 4
- 主要终点
- Compare eye dryness following laser-assisted in situ keratomileusis (LASIK) surgery to eye dryness prior to receiving perioperative Miebo in patients with dry eye disease (DED) as measured by visual analog scale (VAS) eye dryness score
研究概览
简要总结
Compare eye dryness following laser-assisted in situ keratomileusis (LASIK) surgery to eye dryness prior to receiving perioperative Miebo in patients with dry eye disease (DED)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be at least 18 years of age at the time of consent, able to provide written voluntary informed consent, willing to follow instructions and participate in all trial assessments and visits
- •Be a candidate for routine, uncomplicated bilateral LASIK surgery (for spherical equivalent [≤-8.00D] myopia or myopic astigmatism correction, not combined with any other procedure; monovision myopic targets are allowed, however the myopic target eye will be the non-study [fellow] eye)
- •No history of refractive surgery including implantable Collamer lens (ICL) or cataract surgery
- •Total CFS score ≥1 and ≤6 using the National Eye Institute scale at Visit 1 (in at least one eye)
- •Ocular Surface Disease Index (OSDI) ≥13 and ≤22 at Visit 1
排除标准
- •Have any clinically significant ocular surface slit-lamp findings in the study eye that, in the opinion of the Investigator, could interfere with outcomes of a routine, uncomplicated LASIK surgery, including but not limited to:
- •History of eye trauma/surgery within the last 6 months that resulted in corneal scarring
- •DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells, Stevens-Johnson syndrome, active blepharitis, or lid margin inflammation
- •Abnormal cornea (e.g., keratoconus or corneal epithelial defect, pterygium, or history of herpetic keratitis)
- •Use of any of the following ocular therapies in the study eye within 30 days prior to Visit 1: topical ocular steroid treatments, prescription dry eye therapy (including nasal spray), or topical intraocular pressure-lowering medications
- •Use of any eye drops (prescription or over the counter) in the study eye within 24 hours prior to Visit 1
- •Use of any oral medications known to cause ocular drying (e.g., antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or is expected to be unstable during the trial
- •Had a LipiFlow®, intense pulsed light (IPL) therapy, etc. in the study eye within 3 months prior to Visit 1
- •Had received or removed a permanent punctum plug in the study eye within 1 month (3 months for dissolvable punctum plugs) prior to Visit 1
- •Have worn soft contact lenses within either 3 days prior to the study or rigid gas-permeable contact lenses for 1 month prior to Visit 1 or any planned wear during the study
- •Have undergone intraocular surgery or ocular laser surgery in the study eye within 3 months prior to Visit 1
- •Have ocular allergies that are/expected to be active during the trial period
- •Have active ocular or systemic infection (bacterial, viral, or fungal), including fever
- •Have any ocular findings or uncontrolled systemic disease that, in the opinion of the Investigator, will interfere with the trial
- •Female subjects who are pregnant, nursing, or planning a pregnancy
- •Female subjects of childbearing potential who are not using an acceptable means of birth control; acceptable methods of contraception include hormonal (oral, implantable, injectable, or transdermal) contraception; mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom) contraception; intrauterine device; or surgical sterilization of partner. For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.
- •Have a known allergy and/or sensitivity or lack of desired efficacy in response to the investigational drug
- •Are currently enrolled in an investigational drug or device study or had used an investigational drug or device within 30 days prior to Visit 1 -
研究组 & 干预措施
Miebo
Active Comparator
Miebo instilled four times per day to each eye
干预措施: Miebo four times per day (Drug)
结局指标
主要结局
Compare eye dryness following laser-assisted in situ keratomileusis (LASIK) surgery to eye dryness prior to receiving perioperative Miebo in patients with dry eye disease (DED) as measured by visual analog scale (VAS) eye dryness score
时间窗: 4 months
Visual analog scole with a minimum score of 0 (lowest rating) and maximum score of 100 (highest rating)
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
尚未招募
2 期
Effect of acupuncture on dry eye diseaseCTRI/2024/04/066271Dr V Madhumitha68
Unknown
不适用
评价 OptiLight 用于角膜屈光手术围手术期干眼管理安全性和有效性的前瞻性、单中心、随机对照研究ChiCTR2500103809自选课题（自筹）30
已完成
3 期
A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseaseNCT07284381AbbVie261
Enrolling By Invitation
不适用
Microbiome-Focused Food Supplement for Evaporative Dry Eye Due to Meibomian Gland DysfunctionDry EyeNCT07453212Varol TUNALI130
Unknown
不适用
请于伦理委员会批准后才开始征募参试者，并与我们联系上传伦理批件。 3%地夸磷索钠治疗 FS-LASIK 术后轻中度干眼的疗效研究ChiCTR2100048889公司赞助240